Cost-effectiveness of first-line induction and maintenance treatment sequences in non-squamous non-small cell lung cancer (NSCLC) in the U.S.

Lung Cancer ◽

10.1016/j.lungcan.2015.05.020 ◽

2015 ◽

Vol 89 (3) ◽

pp. 294-300 ◽

Author(s):

Gayathri Kumar ◽

Beth Woods ◽

Lisa M. Hess ◽

Joseph Treat ◽

Mark E. Boye ◽

...

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Maintenance Treatment ◽

Small Cell Lung ◽

The U.S ◽

Treatment Sequences

Download Full-text

A cost-effectiveness analysis of first-line induction and maintenance treatment sequences in patients with advanced nonsquamous non-small-cell lung cancer in France

ClinicoEconomics and Outcomes Research ◽

10.2147/ceor.s128371 ◽

2017 ◽

Vol Volume 9 ◽

pp. 505-518 ◽

Author(s):

Kaisa Taipale ◽

Katherine B Winfree ◽

Mark Boye ◽

Mickael Basson ◽

Ghassan Sleilaty ◽

...

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Maintenance Treatment ◽

Cost Effectiveness Analysis ◽

Small Cell Lung ◽

Effectiveness Analysis

Download Full-text

Cross-market cost-effectiveness analysis of erlotinib as first-line maintenance treatment for patients with stable non-small cell lung cancer

ClinicoEconomics and Outcomes Research ◽

10.2147/ceor.s25923 ◽

2012 ◽

pp. 31 ◽

Author(s):

Alain Vergnenègre ◽

Ray ◽

christos chouaid ◽

Grossi ◽

Bischoff ◽

...

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Maintenance Treatment ◽

Cost Effectiveness Analysis ◽

Small Cell Lung ◽

Effectiveness Analysis

Download Full-text

Cost-Effectiveness Analysis of Afatinib, Erlotinib, and Gefitinib as First-Line Treatments for EGFR Mutation-Positive Non-Small-Cell Lung Cancer in Ontario, Canada

PharmacoEconomics ◽

10.1007/s40273-021-01022-9 ◽

2021 ◽

Author(s):

Yong-Jin Kim ◽

Mark Oremus ◽

Helen H. Chen ◽

Thomas McFarlane ◽

Danielle Fearon ◽

...

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Egfr Mutation ◽

Cost Effectiveness Analysis ◽

Small Cell Lung ◽

Effectiveness Analysis

Download Full-text

PCN44 COST COMPARISON OF ERLOTINIB VERSUS PEMETREXED FOR THE FIRST-LINE MAINTENANCE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER IN SPAIN

Value in Health ◽

10.1016/s1098-3015(11)71940-4 ◽

2010 ◽

Vol 13 (7) ◽

pp. A259 ◽

Author(s):

J Castro de Carpeño ◽

AJ Castro-Gómez ◽

S Walzer ◽

J Ray

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Maintenance Treatment ◽

Locally Advanced ◽

Cost Comparison ◽

Small Cell Lung ◽

Download Full-text

Cost-Effectiveness of Eml4-Alk Gene Targeted First-Line Ceritinib Treatment Among Patients With Advanced Alk-Positive Non–Small Cell Lung Cancer

Value in Health ◽

10.1016/j.jval.2015.03.1177 ◽

2015 ◽

Vol 18 (3) ◽

pp. A203

Author(s):

N. Upadhyay ◽

N. Atreja

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell Lung ◽

Download Full-text

Cost-effectiveness of ALK testing and first-line crizotinib therapy for non-small-cell lung cancer in China

PLoS ONE ◽

10.1371/journal.pone.0205827 ◽

2018 ◽

Vol 13 (10) ◽

pp. e0205827 ◽

Author(s):

Shun Lu ◽

Yongfeng Yu ◽

Shijun Fu ◽

Hongye Ren

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell Lung ◽

Download Full-text

Cost-effectiveness of afatinib, gefitinib, erlotinib and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China

Lung Cancer ◽

10.1016/j.lungcan.2018.11.029 ◽

2019 ◽

Vol 127 ◽

pp. 84-89 ◽

Author(s):

Xiaohua Gu ◽

Qiang Zhang ◽

Yun-Bo Chu ◽

Yi-Yang Zhao ◽

Yan-Jun Zhang ◽

...

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell Lung ◽

Download Full-text

Cost-effectiveness analysis of first-line pembrolizumab treatment for PD-L1 positive, non-small cell lung cancer in China

Journal of Medical Economics ◽

10.1080/13696998.2019.1570221 ◽

2019 ◽

Vol 22 (4) ◽

pp. 344-349 ◽

Author(s):

Weiting Liao ◽

Jiaxing Huang ◽

David Hutton ◽

Qiu Li

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Cost Effectiveness Analysis ◽

Small Cell Lung ◽

Effectiveness Analysis

Download Full-text

Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab vs. Chemotherapy as First-Line Therapy in Advanced Non-Small Cell Lung Cancer

Frontiers in Oncology ◽

10.3389/fonc.2020.01649 ◽

2020 ◽

Vol 10 ◽

Author(s):

Huabin Hu ◽

Longjiang She ◽

Mengting Liao ◽

Yin Shi ◽

Linli Yao ◽

...

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell Lung ◽

First Line Therapy ◽

Effectiveness Analysis ◽

Download Full-text

PCN116 COST-EFFECTIVENESS OF PEMBROLIZUMAB (KEYTRUDA®) PLUS PLATINUM-PEMETREXED FOR FIRST-LINE TREATMENT OF METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER IN FRANCE

Value in Health ◽

10.1016/j.jval.2019.09.313 ◽

2019 ◽

Vol 22 ◽

pp. S458

Author(s):

C. Chouaid ◽

L. Bensimon ◽

A. Millier ◽

E. Clay ◽

R. Insinga ◽

...

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Line Treatment ◽

Small Cell Lung ◽

First Line Treatment

Download Full-text